Celldex Therapeutics


Monday Morning Market Insights: KaloBios Pharmaceuticals Inc (KBIO), Chipotle Mexican Grill, Inc. (CMG), Celldex Therapeutics, Inc. (CLDX), Sarepta Therapeutics Inc (SRPT)

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) soaring 30% in early morning trading, adding to their 20% rise after Friday’s news that the company appointed Martin Shkreli as …

Company Update (NASDAQ:CLDX): Independent Data Safety and Monitoring Board Recommends Continuation of Celldex Therapeutics, Inc.’s Phase 3 Study of RINTEGA(R)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study …

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Reports First Quarter 2015 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2015.

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and …

Roth Capital Reiterates Buy On Celldex Therapeutics; Encouraged By The BTD Designation For Rintega

Celldex Therapeutics, Inc. (NASDAQ:CLDX) received another set of praises from analysts at Roth Capital, in addition to analysts at Cowen and Brean Capital.

Cowen & Co Shares Positive Outlook On Celldex Therapeutics Following FDA ‘Breakthrough’ Approval

Shares of Celldex Therapeutics (NASDAQ: CLDX) shot up about 17.5% in trading on February 23rd following the company’s announcement that it was granted FDA approval …

Stock Update (NASDAQ:CLDX): Celldex Reports Fourth Quarter and Year-End 2014 Results

Celldex Therapeutics, Inc. (Nasdaq:CLDX) reported business and financial highlights for the fourth quarter and year ended December 31, 2014.